Coherus Oncology, Inc. - Common Stock, $0.0001 par value per share (CHRS) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2014 to Q4 2025

Type / Class
Equity / Common Stock, $0.0001 par value per share
Symbol
CHRS on Nasdaq
Shares outstanding
116,964,738
Price per share
$1.42
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
51,568,692
Total reported value
$84,529,392
% of total 13F portfolios
0%
Share change
-3,717,047
Value change
-$2,975,455
Number of holders
111
Price from insider filings
$1.42
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Coherus Oncology, Inc. - Common Stock, $0.0001 par value per share (CHRS) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 6.6% -30% $6,398,869 -$2,904,900 7,617,701 -31% BlackRock, Inc. 31 Mar 2025
Bering Partners II, L.P. 6.5% $12,468,441 7,602,708 Evgeny Zaytsev ("Zaytsev") 05 Sep 2025
SATTERFIELD THOMAS A JR 5.2% $5,047,992 6,009,514 Thomas A. Satterfield, Jr. 14 Apr 2025
Rubric Capital Management LP 4.6% $4,417,353 5,258,754 Rubric Capital Management LP 31 Dec 2024

As of 30 Sep 2025, 111 institutional investors reported holding 51,568,692 shares of Coherus Oncology, Inc. - Common Stock, $0.0001 par value per share (CHRS). This represents 44% of the company’s total 116,964,738 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Coherus Oncology, Inc. - Common Stock, $0.0001 par value per share (CHRS) together control 41% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 8.9% 10,459,986 -2.6% 0% $17,154,377
VANGUARD GROUP INC 8.8% 10,321,107 -2.4% 0% $16,926,616
TANG CAPITAL MANAGEMENT LLC 4.4% 5,097,362 0% 0.32% $8,359,674
Kohlberg Kravis Roberts & Co. L.P. 2.6% 3,036,076 0% 0.08% $4,931,401
GEODE CAPITAL MANAGEMENT, LLC 2.3% 2,741,226 +2.4% 0% $4,496,453
STATE STREET CORP 1.9% 2,223,376 +0.22% 0% $3,646,337
CM Management, LLC 1.8% 2,100,000 -6.7% 2.9% $3,444,000
C WorldWide Group Holding A/S 1.6% 1,928,464 0% 0.05% $3,163,000
PANAGORA ASSET MANAGEMENT INC 1.2% 1,375,968 +73% 0.01% $2,256,588
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.85% 993,092 +1.2% 0% $1,628,671
AQR CAPITAL MANAGEMENT LLC 0.77% 903,037 +17% 0% $1,480,981
MACQUARIE GROUP LTD 0.77% 899,999 0% 0% $1,476,000
NORTHERN TRUST CORP 0.73% 850,418 -5.1% 0% $1,394,685
Hudson Bay Capital Management LP 0.69% 810,000 -3% 0.01% $1,328,400
UBS Group AG 0.68% 795,941 +39% 0% $1,305,343
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.35% 403,913 +8.1% 0% $662,417
GOLDMAN SACHS GROUP INC 0.33% 382,780 +16% 0% $627,759
Bank of New York Mellon Corp 0.32% 376,685 -3.5% 0% $617,763
ROYAL BANK OF CANADA 0.29% 335,498 -1.3% 0% $551,000
CITADEL ADVISORS LLC 0.28% 331,155 +147% 0% $543,094
Jefferies Financial Group Inc. 0.28% 325,625 +2.5% 0% $534,025
STRS OHIO 0.28% 324,000 0% 0% $531,360
BARCLAYS PLC 0.25% 293,192 -1.5% 0% $480,835
Invesco Ltd. 0.22% 260,992 +25% 0% $428,027
BRIDGEWAY CAPITAL MANAGEMENT, LLC 0.22% 255,000 +78% 0.01% $418,200

Institutional Holders of Coherus Oncology, Inc. - Common Stock, $0.0001 par value per share (CHRS) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 132,201 $185,804 +$39,928 $1.42 6
2025 Q3 51,568,692 $84,529,392 -$2,975,455 $1.64 111
2025 Q2 55,358,578 $40,439,575 -$4,928,957 $0.73 109
2025 Q1 62,082,313 $50,064,571 -$6,457,965 $0.81 114
2024 Q4 65,593,316 $90,486,342 -$12,493,568 $1.38 121
2024 Q3 76,943,748 $79,924,833 -$11,982,913 $1.04 128
2024 Q2 81,741,478 $141,415,904 -$567,474 $1.73 132
2024 Q1 82,490,902 $197,155,233 -$7,273,789 $2.39 133
2023 Q4 320,175 $1,066,183 +$719,893 $3.33 3
2023 Q3 92,949,604 $347,548,461 +$14,455,001 $3.74 167
2023 Q2 86,685,207 $370,291,227 +$30,644,863 $4.27 159
2023 Q1 78,433,333 $536,456,583 -$2,031,047 $6.84 163
2022 Q4 78,590,353 $622,337,026 +$4,098,794 $7.92 158
2022 Q3 76,868,092 $738,604,939 -$15,160,885 $9.61 164
2022 Q2 78,050,203 $565,768,639 +$17,998,892 $7.24 168
2022 Q1 75,369,979 $972,369,931 -$14,978,773 $12.91 168
2021 Q4 75,787,941 $1,210,544,602 +$10,300,988 $15.96 187
2021 Q3 74,837,672 $1,203,545,861 -$20,590,565 $16.07 181
2021 Q2 76,973,958 $1,065,028,464 -$38,213,367 $13.83 181
2021 Q1 79,446,478 $1,161,788,582 -$124,630,987 $14.61 200
2020 Q4 86,063,811 $1,495,912,138 +$7,554,889 $17.38 188
2020 Q3 87,614,483 $1,608,852,964 -$15,467,754 $18.34 198
2020 Q2 86,469,808 $1,543,870,492 +$222,981,430 $17.86 184
2020 Q1 70,343,055 $1,141,301,709 +$20,759,271 $16.22 181
2019 Q4 72,260,806 $1,300,999,134 +$58,157,061 $18.00 182
2019 Q3 68,733,742 $1,392,557,172 +$50,170,483 $20.26 162
2019 Q2 66,160,770 $1,459,343,817 +$24,698,296 $22.10 140
2019 Q1 64,573,411 $880,797,508 +$50,923,521 $13.64 112
2018 Q4 63,295,431 $572,802,982 -$18,001,423 $9.05 105
2018 Q3 57,021,480 $940,856,419 +$38,878,477 $16.50 104
2018 Q2 61,890,449 $866,492,516 +$96,239,342 $14.00 111
2018 Q1 55,290,055 $610,960,009 +$32,856,198 $11.05 102
2017 Q4 49,102,379 $432,094,054 +$14,808,501 $8.80 90
2017 Q3 46,927,893 $626,702,945 +$87,706,037 $13.35 90
2017 Q2 39,654,663 $569,049,532 +$24,360,105 $14.35 102
2017 Q1 37,278,747 $787,972,353 +$211,222,922 $21.15 107
2016 Q4 29,564,710 $831,825,230 +$50,937,939 $28.15 120
2016 Q3 27,764,815 $743,459,042 +$77,913,079 $26.78 115
2016 Q2 25,316,503 $427,586,064 +$112,052,481 $16.89 84
2016 Q1 17,965,369 $381,329,000 +$29,117,184 $21.23 72
2015 Q4 16,638,977 $382,049,785 +$9,733,303 $22.96 76
2015 Q3 14,522,663 $291,029,715 +$15,563,695 $20.04 74
2015 Q2 14,936,029 $430,594,071 +$228,173,472 $28.90 71
2015 Q1 5,713,066 $174,108,439 -$28,137,711 $30.58 48
2014 Q4 8,294,657 $132,174,817 +$132,163,604 $16.32 35